145 related articles for article (PubMed ID: 31933288)
1. Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Hollis KA; Djokanovic N; Racanelli VS; Petraro P; Vassilev ZP
Pharmaceut Med; 2019 Jun; 33(3):235-246. PubMed ID: 31933288
[TBL] [Abstract][Full Text] [Related]
2. Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Hollis KA; Schmidt-Ott UM; Petraro P; Vassilev ZP
Pharmaceut Med; 2019 Jun; 33(3):219-233. PubMed ID: 31933286
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.
Zografos LJ; Andrews E; Wolin DL; Calingaert B; Davenport EK; Michel A; Latocha M; Schmidt-Ott UM; Lovic N; Brunck LR; Johnson KT; Suzart-Woischnik K
Pharmaceut Med; 2024 Jan; 38(1):63-73. PubMed ID: 38049618
[TBL] [Abstract][Full Text] [Related]
4. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
7. Postmarketing analysis of aflibercept-related sterile intraocular inflammation.
Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
JAMA Ophthalmol; 2015 Apr; 133(4):421-6. PubMed ID: 25590968
[TBL] [Abstract][Full Text] [Related]
8. [Management algorithm of age-related macular degeneration with aflibercept: Real-life application].
Gualino V; Baillif S; Kodjikian L
J Fr Ophtalmol; 2016 Dec; 39(10):872-879. PubMed ID: 27789040
[TBL] [Abstract][Full Text] [Related]
9. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
[TBL] [Abstract][Full Text] [Related]
11. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study.
Lashay A; Delrish E; Ashrafi E; Movassat M; Asadi-Amoli F; Dinarvand R; Abrishami M
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):785-790. PubMed ID: 31877224
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
13. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
Singh N; Chang JS; Rachitskaya AV
Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
[TBL] [Abstract][Full Text] [Related]
14. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT.
Yogi R; Stewart M; Chhablani J
Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection.
Bilgin B; Bilak Ş
Middle East Afr J Ophthalmol; 2019; 26(2):55-59. PubMed ID: 31543660
[TBL] [Abstract][Full Text] [Related]
16. Safety of bilateral intravitreal injections delivered in a teaching institution.
Chao DL; Gregori NZ; Khandji J; Goldhardt R
Expert Opin Drug Deliv; 2014 Jul; 11(7):991-3. PubMed ID: 24815986
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of Intravitreal Aflibercept Injections in Patients who had Received 10 and More Ranibizumab Injections in Advance].
Lenk J; Matthé E; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2016 Mar; 232(3):284-9. PubMed ID: 26562136
[TBL] [Abstract][Full Text] [Related]
18. Prefilled syringes for intravitreal injection reduce preparation time.
Subhi Y; Kjer B; Munch IC
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034182
[TBL] [Abstract][Full Text] [Related]
19. Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab.
Grewal DS; Schwartz T; Fekrat S
Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):428-431. PubMed ID: 28499055
[TBL] [Abstract][Full Text] [Related]
20. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.
Goldberg RA; Shah CP; Wiegand TW; Heier JS
Am J Ophthalmol; 2014 Oct; 158(4):733-737.e1. PubMed ID: 24983791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
